News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
New Day Diagnostics Collaboration
Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing Spondylitis Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing...
Augurex has received $5M in funding from PacifiCan
Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care
Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
14-3-3η: How Joint Involvement “Spreads”
14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η's clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to assess...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
Commitment to Access, Quality and Growth through Innovation
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3ƞ) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives...
Natalie Dakers: Chair of Augurex’s Board of Directors Receives 2019 Milton Wong Award
Augurex is very proud to announce that Natalie Dakers, Chair of our Board of Directors, has been awarded the 2019 Milton Wong Award. Natalie’s award is well-deserved given her outstanding leadership and notable impact on the Life Sciences ecosystem, which Augurex has...
USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex's Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated...
14-3-3η: How Joint Involvement “Spreads”
14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η's clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to assess...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
Commitment to Access, Quality and Growth through Innovation
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3ƞ) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives...
Natalie Dakers: Chair of Augurex’s Board of Directors Receives 2019 Milton Wong Award
Augurex is very proud to announce that Natalie Dakers, Chair of our Board of Directors, has been awarded the 2019 Milton Wong Award. Natalie’s award is well-deserved given her outstanding leadership and notable impact on the Life Sciences ecosystem, which Augurex has...
USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex's Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated...
More Precise RA Patient Care; New data on the 14-3-3η blood test to help optimize treat-to-target strategies
At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several...
Digital Technology Supercluster Member Spotlight
Did you miss the Digital Technology Supercluster Member Spotlight on Augurex? Read how Augurex will be working alongside Supercluster members like Telus Health, Providence Health Care, Microsoft and LifeLabs Medical Laboratory Services to advance patient-centric...
2018 Ready to Rocket Winner
Honored to be recognized by "Ready to Rocket" as one of the 10 featured Life Sciences companies to experience accelerated growth. We're excited for the future! About Ready to Rocket: Ready to Rocket is a unique business recognition list that profiles technology...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact